Jim Cramer on Baxter: "They Are the King of Disappointment"

Baxter International Inc. (NYSE:BAX) is one of the stocks Jim Cramer recently gave takes on. A caller asked whether they should continue to hold or sell the stock, and Cramer commented:

“Oh my god, you know, Baxter, go buy Abbott Labs. I mean, I gotta tell you, Baxter’s been such an incredible disappointment. It’s painful. I don’t know why they continue to disappoint. They are the king of disappointment, and that’s saying something. I’m, you know, the knight of disappointment or the bishop. They’re the king.”

Baxter International Inc. (NYSE:BAX) provides medical devices, pharmaceuticals, and digital health technologies used across hospitals, clinics, and home care. Its products include IV solutions, infusion systems, surgical products, respiratory devices, and specialty injectables. Here is what Parnassus Investments has to say about Baxter International Inc. (NYSE:BAX) in its second-quarter 2025 investor letter:

“Despite Baxter International Inc.’s (NYSE:BAX) defensive characteristics, we became concerned about its capital allocation decisions, recent management changes and sensitivity to hospital budgets. We traded Baxter for Linde, where we see higher long-term risk-reward potential.”

While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.